Vivaxのマラリアは,クロロクインによる治療と予防に耐性がある
1US Naval Medical Research Unit No 2, Jakarta, Indonesia.
Lancet (London, England)
|January 9, 1993
まとめ
プラズモディウムビバックスマラリアにおけるクロロクイン耐性菌は,インドネシアで発生しています. クロロクインは,この地域では,特に幼児において,ビバックスマラリアの治療または予防に効果的ではない.
科学分野:
- トロピカル・メディシン (熱帯医学)
- 感染症 感染症は感染症です.
- 寄生虫学とは,寄生虫学である.
背景:
- クロロクインは40年以上にわたってvivaxマラリアの標準治療法となっています.
- 最近の症例報告は,パプアニューギニアとインドネシアのPlasmodium vivaxに,クロロクイン耐性が生じたことを示唆している.
研究 の 目的:
- プラズモディウムビバックス感染に対するクロロキンの治療と予防の有効性を評価する. インドネシア,イリアンジャヤ.
主な方法:
- クロロクインで治療されたP. vivax寄生病の46人の村人を対象とした将来的な治療試験.
- 寄生虫のクリアランスと再発をモニタリングするために14日間フォローアップ.
- 初期感染をクリアした被験者に対して,毎週クロロクインを投与した予防試験.
主要な成果:
- 最初の寄生虫クリアランスはすべての被験者に発生したが,22%が14日以内に再発を経験した.
- 再発率は4歳未満の子供で最も高く (70%の失敗率) でした.
- クロロクインの予防は効果がなく,被験者の53%が8週間以内に寄生病を発症した.
結論:
- クロロクインは,ニューギニアのこの地域で,P. vivaxマラリアに対する信頼性の高い治療法ではありません.
- クロロロキンの化学予防療法も,イリアンジャヤで得られたP. vivaxの感染に対して無効です.
- クロロクイン耐性の出現は,代替的なマラリア対策戦略を必要とします.
関連する概念動画
Symbiosis
Symbiotic relationships are long-term, close interactions between individuals of different species that affect the distribution and abundance of those species. When a relationship is beneficial to both species, this is called mutualism. When the relationship is beneficial to one species but neither beneficial nor harmful to the other species, this is called commensalism. When one organism is harmed to benefit another, the relationship is known as parasitism. These types of relationships often...
Diversity of Protists II
Alveolates are a group of organisms recognized by the presence of alveoli, which are cytoplasmic sacs located beneath the cell membrane. While their function remains uncertain, alveoli may help regulate water balance by controlling how much water enters and leaves the cell. In dinoflagellates, these structures may serve as armor plates. There are three major types of alveolates: ciliates, which move using cilia; dinoflagellates, which use flagella for movement; and apicomplexans, which are...
Malaria
Malaria pathogenesis in humans reflects a delicate interplay between parasite biology and host response. Clinical illness reflects a host’s immune response to the parasite’s asexual replication cycle, which is often asymptomatic in individuals with partial immunity. From the parasite's perspective, transmission between mosquito and human with minimal host pathology is evolutionarily advantageous. Among the six Plasmodium species infecting humans, P. falciparum and P. vivax dominate in global...
American Trypanosomiasis
Chagas disease, or American trypanosomiasis, is a vector-borne parasitic infection caused by Trypanosoma cruzi, a flagellated protozoan (kinetoplastid) of the family Trypanosomatidae. The disease is endemic in Latin America, although cases are increasingly reported worldwide due to human migration. Transmission most commonly occurs when feces of infected triatomine bugs contaminate bite wounds or mucosal surfaces; additional routes include congenital, transfusional, transplant-related, and oral...
Anthelminthic Agents
Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...


